Osivax and GC Biopharma unveiled a strategic collaboration aimed at developing a next-generation influenza vaccine. The vaccine aims to combine OVX836 and GC FLU. Osivax obtained the rights to advance a combo shot.
Older adults face four vaccine decisions this fall, while the national vaccine schedule continues to carry a 2025 date. Flu and pneumonia deaths have fallen for 25 years, but one American age group saw an increase.